Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Oric Pharmaceuticals Inc (ORIC)

$8.83 -0.16 (-1.78%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	930.63M
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	908,100
Avg Vol	1,936,928
Day's Range	N/A - N/A
Shares Out	103.52M
Stochastic %K	8%
Beta	1.11
Analysts	Strong Sell
Price Target	$20.77

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 388 5600

Website: www.oricpharma.com

Address:

240 E. Grand Ave, 2nd Floor, South San Francisco, United States

SuperGreenToday Apr. 30 at 5:12 AM

$ORIC Share Price: $9.44 Contract Selected: Aug 21, 2026 $10 Calls Buy Zone: $2.45 – $3.02 Target Zone: $4.11 – $5.02 Potential Upside: 58% ROI Time to Expiration: 113 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing Apr. 28 at 6:35 PM

$ORIC Current Stock Price: $9.60 Contracts to trade: $10.0 ORIC May 15 2026 Call Entry: $1.80 Exit: $2.26 ROI: 25% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Chrissixdd Apr. 25 at 2:50 PM

been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too

0 · Reply

MOTP Apr. 22 at 12:45 PM

$ORIC when is the Q1 ER for this one?

1 · Reply

th3_fail_k1ng Apr. 18 at 12:22 AM

$ORIC

0 · Reply

BlakeCanyon50 Apr. 17 at 12:53 PM

$ORIC 🤔. At 0%… No Movement… 🤓

0 · Reply

abasol64 Apr. 16 at 3:04 PM

$ADMA and $ORIC slowly to 16

0 · Reply

newfq Apr. 14 at 2:58 PM

$ORIC

0 · Reply

username0055 Apr. 13 at 7:58 PM

$ORIC Well that was stupid.

0 · Reply

BlakeCanyon50 Apr. 13 at 2:11 PM

$ORIC ✅❤️🙏🏼

0 · Reply

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Apr 6, 2026, 8:06 AM EDT - 5 weeks ago

ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Oric selloff brings attractive entry point, says H.C. Wainwright

2026-04-02T10:16:26.000Z - 5 weeks ago

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Mar 27, 2026, 8:30 AM EDT - 6 weeks ago

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Mar 17, 2026, 5:01 PM EDT - 2 months ago

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Oric selloff brings favorable entry point, says H.C. Wainwright

2026-03-13T10:15:48.000Z - 2 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 5, 2025, 1:00 AM EST - 5 months ago

ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

Dec 4, 2025, 9:45 PM EST - 5 months ago

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

Dec 3, 2025, 4:01 PM EST - 5 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

Dec 3, 2025, 11:15 AM EST - 5 months ago

ORIC Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 8:00 AM EST - 5 months ago

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 6 months ago

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Nov 11, 2025, 1:30 PM EST - 6 months ago

ORIC Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:00 PM EST - 6 months ago

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Oct 27, 2025, 8:30 AM EDT - 7 months ago

ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors

ORIC Pharmaceuticals Transcript: Baird Global Healthcare Conference 2025

Sep 10, 2025, 1:25 PM EDT - 8 months ago

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

May 27, 2025, 8:00 AM EDT - 1 year ago

ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

May 5, 2025, 4:05 PM EDT - 1 year ago

ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates

Apr 28, 2025, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 9, 2025, 2:00 PM EDT - 1 year ago

ORIC Pharmaceuticals Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 1:30 PM EDT - 1 year ago

ORIC Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:30 PM EDT - 1 year ago

ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Feb 25, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Feb 18, 2025, 4:05 PM EST - 1 year ago

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 1 year ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

ORIC Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 8:35 AM EDT - 1 year ago

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

Jul 16, 2024, 4:59 PM EDT - 1 year ago

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 10, 2024, 10:40 AM EDT - 2 years ago

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

Apr 11, 2024, 3:45 PM EDT - 2 years ago

ORIC Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 8, 2024, 8:00 AM EDT - 2 years ago

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 11, 2024, 4:05 PM EDT - 2 years ago

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Mar 6, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 21, 2024, 3:00 PM EST - 2 years ago

ORIC Pharmaceuticals Transcript: Citi 2024 Virtual Oncology Leadership Summit

Feb 14, 2024, 4:30 PM EST - 2 years ago

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

SuperGreenToday Apr. 30 at 5:12 AM

0 · Reply

BillionerOfKing Apr. 28 at 6:35 PM

0 · Reply

Chrissixdd Apr. 25 at 2:50 PM

been digging through the industry and $SLNO is in the cheaper bucket. $RCKT $ORIC $CLYM $DNA nearby too

0 · Reply

MOTP Apr. 22 at 12:45 PM

$ORIC when is the Q1 ER for this one?

1 · Reply

th3_fail_k1ng Apr. 18 at 12:22 AM

$ORIC

0 · Reply

BlakeCanyon50 Apr. 17 at 12:53 PM

$ORIC 🤔. At 0%… No Movement… 🤓

0 · Reply

abasol64 Apr. 16 at 3:04 PM

$ADMA and $ORIC slowly to 16

0 · Reply

newfq Apr. 14 at 2:58 PM

$ORIC

0 · Reply

username0055 Apr. 13 at 7:58 PM

$ORIC Well that was stupid.

0 · Reply

BlakeCanyon50 Apr. 13 at 2:11 PM

$ORIC ✅❤️🙏🏼

0 · Reply

abasol64 Apr. 10 at 1:21 PM

$ADMA and $ORIC to 16

0 · Reply

th3_fail_k1ng Apr. 9 at 9:45 PM

$ORIC like I said that discount wasn't going to last long

0 · Reply

SuperNaros Apr. 9 at 8:10 PM

$ORIC does someone else See that huge jump AH?

0 · Reply

BlakeCanyon50 Apr. 9 at 7:31 PM

$ORIC 🙏🏼❤️🙏🏼

0 · Reply

abasol64 Apr. 8 at 7:50 AM

$ADMA and $ORIC to 16 sooner then you think

0 · Reply

abasol64 Apr. 7 at 12:50 PM

$ORIC and $ADMA 16+ infew month

2 · Reply

newfq Apr. 6 at 4:11 PM

$ORIC waiting 15$

0 · Reply

Steviewan Apr. 6 at 2:01 PM

$ORIC

0 · Reply

abasol64 Apr. 6 at 1:32 PM

$ORIC i wait for 16

0 · Reply

MrTumble Apr. 6 at 9:56 AM

$ORIC morning 🌄

0 · Reply

AllStarRoby Apr. 6 at 1:34 AM

$ORIC whats up with this one, why we trending?

0 · Reply

Erect4tech Apr. 6 at 12:43 AM

$ORIC down 4% overnight trading

0 · Reply

1.0.0